May increase incidence of hypotension, hyperkalemia & changes in renal function w/ other agents blocking the RAS eg, ACE inhibitors or aliskiren. May increase K levels w/ K supplements, K-sparing diuretics, salt substitutes containing K or other drugs (eg, heparin). May decrease antihypertensive effects w/ NSAIDs including COX-2 inhibitors; vol-depleted or compromised renal function in elderly. May increase amlodipine plasma conc w/ CYP34A inhibitors (eg, ketoconazole, itraconazole, ritonavir). CYP3A4 inducers (eg, rifampicin,
H. perforatum). May increase systemic exposure to valsartan w/ inhibitors of the uptake transporter (eg, rifampin, ciclosporin) or efflux transporter (eg, ritonavir). May increase lithium conc & toxicity.
Sign Out
